(19)
(11) EP 3 816 178 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
28.12.2022 Bulletin 2022/52

(45) Mention of the grant of the patent:
23.11.2022 Bulletin 2022/47

(21) Application number: 19799774.5

(22) Date of filing: 07.05.2019
(51) International Patent Classification (IPC): 
C07K 7/08(2006.01)
A61K 38/10(2006.01)
C07K 14/415(2006.01)
A61K 38/00(2006.01)
 A23L 33/18(2016.01)
A61P 25/24(2006.01)
C07K 7/06(2006.01)
(52) Cooperative Patent Classification (CPC):
A23L 33/18; C07K 7/08; A61P 25/24; A61K 38/00; C07K 7/06
(86) International application number:
PCT/JP2019/018229
(87) International publication number:
WO 2019/216307 (14.11.2019 Gazette 2019/46)

(54)

PEPTIDE, COMPOSITION, AND METHOD FOR TREATING, PREVENTING, OR AMELIORATING MOOD DISORDER

PEPTID, ZUSAMMENSETZUNG UND VERFAHREN ZUR BEHANDLUNG, VORBEUGUNG ODER LINDERUNG VON GEMÜTSSTÖRUNGEN

PEPTIDE, COMPOSITION, ET MÉTHODES DE TRAITEMENT, DE PRÉVENTION OU D'ATTÉNUATION D'UN TROUBLE DE L'HUMEUR

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 08.05.2018 JP 2018089784

(43) Date of publication of application:
05.05.2021 Bulletin 2021/18

(73) Proprietors:
  • Kyoto University
    Kyoto-shi, Kyoto 606-8501 (JP)
  • Kazusa DNA Research Institute.
    Kisarazu-shi, Chiba 292-0818 (JP)
  • Kameda Seika Co., Ltd.
    Niigata-shi, Niigata 950-0198 (JP)

(72) Inventors:
  • OHINATA Kousaku
    Kyoto-shi, Kyoto 606-8501 (JP)
  • ASAKURA Saho
    Kyoto-shi, Kyoto 606-8501 (JP)
  • SUZUKI Hideyuki
    Kisarazu-shi, Chiba 292-0818 (JP)
  • SATO Masaru
    Kisarazu-shi, Chiba 292-0818 (JP)
  • ITO Akira
    Niigata-shi, Niigata 950-0198 (JP)
  • HIGUCHI Yuki
    Niigata-shi, Niigata 950-0198 (JP)

(74) Representative: Maiwald GmbH 
Elisenhof Elisenstraße 3
80335 München
80335 München (DE)


(56) References cited: : 
WO-A1-2013/129220
JP-A- 2018 002 616
 JP-A- 2018 002 616
   
  • MORITANI CHIE ET AL: "Isolation of activating factors of serotoninN-acetyltransferase from rice peptides", JOURNAL OF FUNCTIONAL FOODS, ELSEVIER BV, NL, vol. 41, 26 December 2017 (2017-12-26), pages 148-154, XP085349202, ISSN: 1756-4646, DOI: 10.1016/J.JFF.2017.12.051
  • MCCLUNG COLLEEN A ED - SANACORA GERARD ET AL: "How Might Circadian Rhythms Control Mood? Let Me Count the Ways", BIOLOGICAL PSYCHIATRY, ELSEVIER SCIENCE, NEW YORK, NY; US, vol. 74, no. 4, 1 April 2013 (2013-04-01), pages 242-249, XP028680322, ISSN: 0006-3223, DOI: 10.1016/J.BIOPSYCH.2013.02.019
  • COLLEEN A MCCLUNG ED - FINEBERG N A ET AL: "Circadian rhythms and mood regulation: Insights from pre-clinical models", EUROPEAN NEUROPSYCHOPHARMACOLOGY, ELSEVIER SIENCE PUBLISHERS BV , AMSTERDAM, NL, vol. 21, 11 August 2011 (2011-08-11), pages S683-S693, XP028292114, ISSN: 0924-977X, DOI: 10.1016/J.EURONEURO.2011.07.008 [retrieved on 2011-07-20]
  • Masaaki Ikeda: "Effects of moodstabilizer on the circadian system: possible implication for abnormalities in mood disorders.", Folia Pharmacologica Japonica, vol. 130, no. 6, 2007, pages 469-476, XP055759075, ISSN: 0015-5691, DOI: 10.1254/fpj.130.469
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).